PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV
PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV
PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
Poster Psoriasis<br />
P 37<br />
MK-3222, an anti-IL23p19 antibody, is safe and effective in the treatment of<br />
psoriasis<br />
Tamara Kopp 1<br />
Elisabeth Riedl 2<br />
Christine Bangert 1<br />
Eli Greisenegger 1<br />
Ann Horowitz 3<br />
Thomas Marbury 4<br />
Robert Stonerock 4<br />
Victor Vidals 5<br />
Jonathan Dosik 6<br />
Claus Zachariae 7<br />
Norbert Reider 8<br />
Alan J Kivitz 9<br />
Danlin Xu 3<br />
Xiaoli Shirley Hou 3<br />
A.S. Zandvliet 3<br />
Matias Morrison 3<br />
Sauzanne Khalilieh 3<br />
1 Department of Dermatology, Division of Immunology, Allergy & Infectious Diseases,<br />
University of Vienna Medical School, Vienna, Austria<br />
2 Department of Dermatology, Division of General Dermatology, University of Vienna<br />
Medical School, Vienna, Austria<br />
3 Merck& Co., Inc., White House Station NJ, USA<br />
4 Orlando Clinical Research Center, Orlando, FL, USA<br />
5 PRA Lenexa, Kansas, USA<br />
6 TKL Research, Inc. Paramus, NJ, USA<br />
7 Department of Dermatology, Gentofte Hospital, University of Copenhagen, Denmark<br />
8 Deptartment of Dermatology, Medical University of Innsbruck, Innsbruck, Austria<br />
9 Altoona Center for Clinical Research Duncansville, PA, USA<br />
Introduction & Objectives: Psoriasis is a chronic inflammatory skin disorder affecting<br />
approximately 2% of people worldwide. The goal of therapy is clearance of psoriatic<br />
plaques. The benchmark response in most clinical trials is a 75% or greater reduction<br />
from the baseline PASI score. Recent discoveries have demonstrated that IL-23dependent<br />
Th17 cells control much of the inflammatory injury that is observed in<br />
diseases such as psoriasis. The safety and efficacy of the anti-IL23p19 antibody,<br />
MK-3222, was assessed in psoriasis.<br />
Materials & Methods: This was a randomized, double-blind, placebo-controlled,<br />
parallel-group dose-ranging, 3-Part, study which evaluated the safety, tolerability,<br />
91